Optiscan Imaging Ltd (ASX: OIL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Optiscan Imaging Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Optiscan Imaging Ltd (ASX: OIL)
Latest News
ASX Share Market News
Why the OptiScan (ASX:OIL) share price is rocketing 26% today
ASX Share Market News
Why the Optiscan (ASX:OIL) share price is going gangbusters
ASX Share Market News
Why the OptiScan (ASX:OIL) share price is climbing higher
ASX Share Market News
Optiscan (ASX:OIL) share price flat on FDA update
OIL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Optiscan Imaging Ltd
Optiscan Imaging Ltd. is engaged in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. It has developed and patented miniaturised confocal microscopes. Its products include FIVE2 and Customisation options. The company was founded by Martin Harris and Peter Maxwell Delaney in 1994 and is headquartered in Mulgrave, Australia.
OIL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 16 Nov 2026 | $0.16 | $0.00 | 0.00% | 90,549 | $0.16 | $0.16 | $0.15 |
| 13 Nov 2026 | $0.16 | $0.00 | 0.00% | 43,104 | $0.16 | $0.16 | $0.16 |
| 12 Nov 2026 | $0.16 | $0.00 | 0.00% | 45,649 | $0.16 | $0.16 | $0.16 |
| 11 Nov 2026 | $0.16 | $-0.01 | -6.25% | 506 | $0.16 | $0.16 | $0.16 |
| 10 Nov 2026 | $0.16 | $0.00 | 0.00% | 123,300 | $0.16 | $0.17 | $0.16 |
| 09 Nov 2026 | $0.16 | $-0.01 | -6.06% | 325,639 | $0.16 | $0.17 | $0.16 |
| 06 Nov 2026 | $0.17 | $0.01 | 6.45% | 199,549 | $0.16 | $0.17 | $0.16 |
| 05 Nov 2026 | $0.16 | $0.01 | 6.67% | 44,066 | $0.16 | $0.16 | $0.16 |
| 04 Nov 2026 | $0.15 | $-0.01 | -6.25% | 81,181 | $0.16 | $0.16 | $0.15 |
| 03 Nov 2026 | $0.16 | $0.01 | 6.67% | 119,167 | $0.15 | $0.16 | $0.15 |
| 02 Nov 2026 | $0.15 | $-0.01 | -6.45% | 163,167 | $0.15 | $0.15 | $0.14 |
| 30 Oct 2026 | $0.16 | $0.01 | 6.67% | 200,756 | $0.15 | $0.16 | $0.15 |
| 29 Oct 2026 | $0.15 | $0.01 | 6.90% | 46,395 | $0.16 | $0.16 | $0.16 |
| 28 Oct 2026 | $0.15 | $0.00 | 0.00% | 22,023 | $0.14 | $0.15 | $0.14 |
| 27 Oct 2026 | $0.14 | $-0.01 | -6.45% | 57,321 | $0.16 | $0.16 | $0.14 |
| 26 Oct 2026 | $0.16 | $-0.01 | -6.25% | 209,042 | $0.16 | $0.16 | $0.15 |
| 23 Oct 2026 | $0.16 | $0.01 | 6.45% | 59,261 | $0.16 | $0.17 | $0.16 |
| 22 Oct 2026 | $0.16 | $0.00 | 0.00% | 60,350 | $0.17 | $0.17 | $0.16 |
| 21 Oct 2026 | $0.16 | $0.00 | 0.00% | 47,973 | $0.16 | $0.16 | $0.15 |
| 20 Oct 2026 | $0.16 | $0.00 | 0.00% | 10,815 | $0.16 | $0.16 | $0.16 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 14 Sep 2026 | Camile Farah | Expiry | 595,981 | $95,356 |
As advised by the company. Rights lapsed
|
| 14 Sep 2026 | Camile Farah | Exercise | 595,981 | $95,356 |
Conversion of securities. 595,981 Performance Rights
|
| 14 Sep 2026 | Camile Farah | Buy | 595,981 | $95,356 |
Conversion of securities.
|
| 09 Sep 2026 | Ronnie (Ron) Song | Issued | 230,502 | $34,575 |
Conversion of securities. nil consideration, value at closing of trading on the day of issue was $0.15 per Share
|
| 09 Sep 2026 | Ronnie (Ron) Song | Exercise | 230,502 | $34,575 |
Conversion of securities. nil consideration, value at closing of trading on the day of issue was $0.15 per Share
|
| 07 Sep 2026 | Robert Cooke | Exercise | 419,094 | $62,864 |
Conversion of securities. Nil consideration
|
| 07 Sep 2026 | Robert Cooke | Issued | 419,094 | $62,864 |
Conversion of securities. Nil consideration
|
| 22 May 2026 | Ronnie (Ron) Song | Sell | 3,000,000 | $360,000 |
Off-market trade.
|
| 13 Jan 2026 | Ronnie (Ron) Song | Issued | 230,502 | $20,745 |
Issue of securities. Performance Rights were issued for nil
consideration. The Company values each Performance Right at $0.12147, 230,502 Performance Rights |
| 13 Jan 2026 | Robert Cooke | Issued | 419,094 | $37,718 |
Issue of securities. 419,094 Performance Rights, Performance Rights were issued for nil
consideration. The Company values each Performance Right at $0.12147 |
| 13 Jan 2026 | Karen Borg | Issued | 230,502 | $20,745 |
Issue of securities. Performance Rights were issued for nil
consideration. The Company values each Performance Right at $0.12147, 230,502 Performance Rights |
| 13 Jan 2026 | Camile Farah | Issued | 1,191,962 | $107,276 |
Issue of securities. Performance Rights were issued as an incentive for nil consideration. The
Company values each Performance Right at $0.12147. 1,191,962 Performance Rights |
| 13 Jan 2026 | Camile Farah | Issued | 6,157,719 | $554,194 |
Issue of options. Options were issued as an incentive for nil consideration. The Company values each B Option at $0.07838.
|
| 19 Dec 2025 | Karen Borg | Transfer | 210,365 | $17,881 |
Off-market transfer. As per announcement on 29-12-2025
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Ronnie (Ron) Song | Non-Executive Director | Feb 2021 |
Mr Song had a 25-year business career in Australia. Ron has established a network of business contacts in areas of enterprise in Asia and Australia. He has contacts in the health sector in Asia as well as associations with businesses and the financial sector in Australia and Asia of value to Optiscan. He is a member of risk committee.
|
| Mr Robert Cooke | Non-Executive ChairmanNon-Executive Director | Apr 2021 |
Mr Cooke has 40 year career in the health industry, his experience spans executive leadership of publicly listed and privately owned healthcare companies, and management of private and public hospitals in Australia, Asia and the UK. Robert is currently the Managing Director of Connelly Partners. Before establishing Connelly Partners in 2018, Robert was the Managing Director & CEO of Healthscope, a private hospital/medical centre/pathology operator between 2010 and 2017. Robert has served as a Director of ASX listed and private equity owned health care companies within Australia and internationally and currently serves as Non-Executive Chair of Genesis Cancer Care, and Midas Healthcare. He is a member of Risk committee.
|
| Ms Karen Borg | Non-Executive Director | Jul 2021 |
Ms Borg has held senior roles in FTSE 100-250 and ASX listed companies in medical devices and consumer products as well as government and not-for-profit human and financial services. Karen has held several Chief Executive Officer positions, including Catholic Healthcare Ltd, Healthdirect and Jobs for NSW. She is a chair of Risk Committee.
|
| Dr Camile Farah | Chief Executive OfficerManaging Director | May 2021 |
Dr Farah is a healthcare executive, clinician-scientist, and global authority in digital diagnostics and precision oncology, with over 25 years of experience leading transformational change across medtech, life sciences, and academic healthcare. He has held CEO, Board, and C-suite roles in medtech and diagnostic companies, commercial strategy, capital raising, global market expansion, and regulatory approvals.
|
| Mr Russell Low | Non-Executive Director | Nov 2026 |
Mr Low is President and Singapore Country Head of the Clermont Group, a Singapore-headquartered international business group founded by New Zealand-born entrepreneur Richard Chandler. Mr Low leads group governance, organisational development and portfolio oversight. He brings direct experience in leading and transforming healthcare organisations. From 2019 to 2021 he was Executive Chairman of Hoan My Medical Corporation. He also served on the board of The Medical City in the Philippines from 2018 to 2022. A lawyer by training, Mr Low served in the Singapore Supreme Court and the Attorney-Generals Chambers before joining Clermont.
|
| Ms Elissa Hansen | Company Secretary | Feb 2025 |
-
|
| Darius Ooi | CFO |
-
|
|
| Elissa Hansen | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Peters Investments Pty Ltd | 395,035,401 | 37.83% |
| HSBC Custody Nominees (Australia) Limited | 195,806,546 | 18.75% |
| Citicorp Nominees Pty Limited | 45,393,860 | 4.35% |
| Ibsen Pty Ltd (Narula Family Set No. 3 A/C) | 38,500,000 | 3.69% |
| Mr Chris Graham and Mrs Diane Graham (C & D Graham S/F A/C) | 13,041,000 | 1.25% |
| Dixson Trust Pty Limited | 10,592,838 | 1.01% |
| Kebin Nominees Pty Ltd | 8,480,599 | 0.81% |
| Mr Camile Farah and Ms Marie Matias (Farah & Matias Family A/C) | 8,184,849 | 0.79% |
| BNP Paribas Noms Pty Ltd | 7,267,386 | 0.78% |
| BNP Paribas Noms Pty Ltd UOBKH A/C R Miers | 6,000,888 | 0.70% |
| Mr Kah Chin Lee | 5,000,000 | 0.57% |
| Ibsen Pty Ltd (Ibsen Superfund A/C) | 4,219,007 | 0.48% |
| Mr Anthony Mark Van Der Steeg | 4,209,448 | 0.40% |
| Mr Christopher John Martin | 4,134,260 | 0.40% |
| Mr Wally Knezevic | 3,515,741 | 0.40% |
| Miss Annabelle Jane Porter | 3,515,741 | 0.33% |
| Sash Pty Ltd (Knezevic Super Fund A/C)i | 3,471,837 | 0.34% |
| Mr James Raymond John Porter | 3,431,837 | 0.33% |
| Mr Jubran William Toak and Mr Melhem William Toak | 3,422,996 | 0.33% |
| Sash Pty Ltd (Knezevic Super Fund A/C)ii | 3,422,223 | 0.33% |